Experimental cell therapy tested for advanced lung cancer
NCT ID NCT06519669
First seen May 02, 2026 · Last updated May 20, 2026 · Updated 3 times
Summary
This study tested a personalized treatment called GT201, made from a patient's own immune cells (tumor-infiltrating lymphocytes), for advanced lung cancer. The goal was to see if it was safe and could shrink tumors. Only 2 people took part, and the study was stopped early, so results are very limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beijing GoBroad Hospital
Beijing, Beijing Municipality, 102200, China
-
Renji Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, 200127, China
Conditions
Explore the condition pages connected to this study.